Jan 16, 2019
On January 9, 2019, Oceanpine Capital held the Oceanpine China Night Healthcare Forum together with Morgan Stanley and Center for Emerging and Neglected Diseases (CEND) of Berkeley at the Li Ka Shing Center at the University of California, Berkeley. The forum attracted dozens of CEOs, scientific research leaders, investors from well-known companies in the biotechnology fields; participants shared development trends in biotechnology, cutting-edge scientific research, business operation insights, and financing needs, and discussed opportunities for cross-border cooperation and industry resource integration.
Looking back at 2018, China has followed the accelerated innovation pace of the world, accompanied by advantageous policies for innovative drugs. Unprofitable early-stage biotechnology companies went listed in Hong Kong under revised rules, and VC and PE have made unprecedented investments in the healthcare industry. Looking into the future, China's healthcare industry will continue to be active in innovation and entrepreneurship. The cooperation with the United States, which is a global leader in research and development, will become increasingly important.
Adam Sun, founding partner of Oceanpine Healtchare Fund, Sam Thong, senior consultant of Morgan Stanley, Julia Schaletzky, executive director of CEND, and Dongjun Ma, Managing Partner of Oceanpine Capital, first welcomed the guests attending China night and introduced the purpose and respective institutions of China Night forum.
Daniel Portnoy, an academician of the American Academy of Sciences and professor of Microbiology and Molecular cytology at the University of California, Berkeley, is a world-renowned pathogenic microbiologist and has established a research platform for Listeria. Professor Portnoy shared his pioneering research on the pathogenesis of Listeria and its application in tumor immunotherapy.
Dr. Nancy T. Chang, senior advisor of Oceanpine Capital and CEO of Ansun BioPharma, an American star biotech company, shared the development trends of biotech industry, her own entrepreneurship and business operation experience in this field, as well as her suggestions to CEOs of start-ups as a well-known investor.
About Oceanpine Capital
Oceanpine Capital is an institutional quality growth equity investment company formed by seasoned entrepreneur and sophisticated investors. We are rooted in China with 20 years of in-depth industry operational and business building experience. Our profound industrial and business partners' (CEO club) network not only enables us to originate true proprietary companies with visible customer and revenues, but also provides tremendous value-added services to our portfolio companies and therefore foster their further growth.